Overview
- 6 inspections across 6 sites are on record.
- 7 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2019-03-22.
At a glance
Inspections
6
Sites
6
Observations
7
Career since
Oct 2017
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Intra-Cellular Therapies Inc | 22 Mar 2019 | Human Drugs | View 483 → |
| Janssen Research & Development, LLC | 4 Feb 2019 | Human Drugs | |
| Jason C. Bermak, M.D., Ph.D. | 13 Dec 2018 | Human Drugs | |
| AstraZeneca Pharmaceuticals LP | 11 Oct 2018 | Human Drugs | |
| 60 Degrees Pharmaceuticals, LLC | 8 Jun 2018 | Human Drugs |
Sites inspected
Intra-Cellular Therapies IncNew York, United States1 insp.
Janssen Research & Development, LLCTitusville, United States1 insp.
Jason C. Bermak, M.D., Ph.D.San Rafael, United States1 insp.
AstraZeneca Pharmaceuticals LPGaithersburg, United States1 insp.
60 Degrees Pharmaceuticals, LLCSilver Spring, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Shirley S Wen2 shared
David L Chon2 shared
Ni A Khin1 shared
Diane C Van Leeuwen1 shared
Mathew T Thomas1 shared
Iram R Hassan1 shared
Robin R Waller1 shared
Jean M Mulinde1 shared
Dustin P Tran1 shared
Melanie N Daniels1 shared
Full investigator report
Get the verbatim findings behind Bei Yu's 7 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site